Navigation Links
Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
Date:9/5/2008

PRINCETON, N.J., Sept. 5 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) management will present at the 3rd Annual Citi Biotech Day being held September 8, 2008, at the Citi Executive Conference Center, New York, NY. Management will also present at the Morgan Stanley Global Healthcare Unplugged Conference on September 9, 2008, at the Grand Hyatt Hotel, New York, NY. Schaefer Price, Pharmasset's Chief Executive Officer, will provide a brief overview of the company followed by a question and answer session at both conferences.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.
Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Kurt Leutzinger

Chief Financial Officer

kurt.leutzinger@pharmasset.com

Office: +1 (609) 613-4110


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
2. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
3. Pharmasset Joins Russell 3000 Index
4. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
5. Pharmasset Selected to Join the NASDAQ Biotechnology Index
6. Pharmasset to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, April 30th
7. Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study
8. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
9. Pharmasset Receives $10 Million of Working Capital
10. Pharmasset Appoints Herbert J. Conrad as a Director
11. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... Participants ... and a high-performance fume hood. Along with the advantages and disadvantages of ductless, ... vs. ducted hoods in the laboratory. , Attendees will learn from an industry ...
(Date:9/19/2017)... ... , ... VetStem Biopharma ’s CEO and founder, Dr. Bob Harman DVM, MPVM, is featured ... Cell Therapy: A Rising Tide". Dr. Harman and Dr. Riordan met in 2003 and ... in the potential of stem cell therapy and a fast friendship was formed. , Dr. ...
(Date:9/19/2017)... ... September 19, 2017 , ... One of the biggest ... eliminated, said Lyle Probst, President, CEO and Founder of ExcitePCR ™. ... pathogen detection solutions, Probst said, “Sample preparation takes place inside our FireflyDX systems, ...
(Date:9/19/2017)... Ann Arbor, MI (PRWEB) , ... September 19, ... ... chemical testing laboratory, is pleased to announce the recipients of its 2017 Science ... academic achievement, exceptional leadership qualities, and involvement with community service defray the costs ...
Breaking Biology Technology:
(Date:3/30/2017)... 30, 2017 Trends, opportunities and forecast in ... by technology (fingerprint, AFIS, iris recognition, facial recognition, hand ... by end use industry (government and law enforcement, commercial ... banking, and others), and by region ( North ... Asia Pacific , and the Rest of ...
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
(Date:3/22/2017)... , March 21, 2017   Neurotechnology ... object recognition technologies, today announced the release of ... (SDK), which provides improved facial recognition using up ... on a single computer. The new version uses ... improve accuracy, and it utilizes a Graphing Processing ...
Breaking Biology News(10 mins):